Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization

This study has been completed.
Sponsor:
Information provided by:
Biopure Corporation
ClinicalTrials.gov Identifier:
NCT00479895
First received: May 25, 2007
Last updated: May 29, 2008
Last verified: May 2008

May 25, 2007
May 29, 2008
April 2007
March 2008   (final data collection date for primary outcome measure)
To study the change in left ventricular relaxation indices and pressure-half time and the change in the sum of ST segment deviations compared to baseline. [ Time Frame: Duration of the study ] [ Designated as safety issue: No ]
To study the change in left ventricular relaxation indices and pressure-half time and the change in the sum of ST segment deviations compared to baseline.
Complete list of historical versions of study NCT00479895 on ClinicalTrials.gov Archive Site
LV hemodynamics; change of ST segment; QCA analysis before and after the no-infusion control occlusion and HBOC-201 infusion/occlusion; safety endpoints [ Time Frame: Duration of the study ]
LV hemodynamics; change of ST segment; QCA analysis before and after the no-infusion control occlusion and HBOC-201 infusion/occlusion; safety endpoints
Not Provided
Not Provided
 
Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization
Phase II, Open-Label Study in the Catheterization Laboratory Setting to Challenge the Concept That HBOC-201 Administration Might Improve Myocardial 'Oxygenation' and Myocardial Function at the Moment of (Brief) Coronary Occlusion

The test compound and subject of this clinical trial is the haemoglobin-based oxygen carrier, HBOC-201 (Hemopure). HBOC-201, initially developed as an alternative to red blood cells for surgical patients, has the ability to restore tissue oxygenation in persistently ischemic tissue. The development of this new class of compounds, referred to as oxygen therapeutics, provides an opportunity to test the safety and efficacy of a new approach to management of myocardial ischemia.

Because of their ability to perfuse and deliver oxygen, hemoglobin-based oxygen carriers (HBOC) may be considered in the treatment of several ischemic conditions, such as acute coronary syndromes (ACS). Elective percutaneous intervention (PCI) induces transient myocardial ischemia due to reduction of coronary flow during balloon inflation in the coronary artery, thus simulating in a control setting, the occurrence of an ACS.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
  • Coronary Occlusion
  • Acute Coronary Syndrome
Drug: Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
Pre-oxygenated HBOC-201
  • 1
    Occlusion with pre-oxygenated HBOC-201 followed by dry occlusion
    Intervention: Drug: Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
  • 2
    Dry occlusion followed by occlusion with pre-oxygenated HBOC-201
    Intervention: Drug: Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
April 2008
March 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed informed consent before initiation of any study-related procedure and agreement to comply with all protocol-specific procedures
  • Stable angina pectoris (CCS Class 1, 2, 3, 4) or unstable angina (Braundwald class 1-3, B) or documented silent ischemia
  • Baseline ECG with stable sinus rhythm and no signs of ischemia and with no Q waves, bundle branch block or IV conduction disturbances.
  • Normal left ventricular wall motion on left ventricular angiogram or on echocardiogram with preserved systolic global LV function
  • Non-occlusive stenosis, located in the proximal segments of the left anterior descending artery (LAD) (segments 6 and/or 7) and/or circumflex artery (CFX) (segments 11 and/or 12) or right coronary artery (RCA) (segments 1, 2 and/or 3) for which there is clinical indication to percutaneous treatment with coronary stenting
  • Successful PCI with stenting on the target vessel
  • Older than 18 years and younger than 80 years of age

Exclusion Criteria:

  • Active ischemia at the initiation of the study procedure
  • Non-ST segment elevation myocardial infarction
  • History or ECG evidence of prior MI in the territory supplied by the vessel undergoing PCI, IV conduction defects/baseline ST-segment abnormalities on the surface ECG
  • Moderate to severe aortic or mitral valve disease
  • Evidence of LV hypertrophy on the echocardiogram IVS > 13 and/or PW > 13mm
  • Angiographically visible collateral vessels to the target vessel
  • Hypertension not adequately controlled by anti-hypertensive therapy at the time of study entry (> 140/100mmHg)
  • Uncompensated congestive heart failure or signs of pulmonary edema
  • Significant hemodynamic compromise and/or cardiogenic shock requiring inotropic or pressor support
  • Contraindications to standard drugs for coronary intervention and coronary heart disease: aspirin, heparin, low molecular weight heparin, clopidogrel, contrast dye
  • Confirmed pregnancy
  • Systemic mastocytosis
  • Hypoxemia (need for mechanical ventilation
  • Known history of COPD with FEV 1s < 1.0 liter
  • Renal impairment: creatinine > 1.6 mg/dl
  • Participation in another trial with an investigational drug or device including follow-up period, within the last 30 days before enrollment

Additional exclusion criteria at the end of PCI (before randomization)

  • Coronary TIMI flow in the treated artery is less than 3
  • Serious arrhythmias during/following the PCI was noted
  • Coronary spasm following PCI
  • Any deterioration in the subject's "risk" status between informed consent and randomization
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00479895
COR-0002
No
Not Provided
Biopure Corporation
Not Provided
Study Director: A. Gerson Greenburg, MD, PhD Biopure Corporation
Biopure Corporation
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP